Melphalan flufenamide

Unassigned

New Medicines

Ygalo · Relapsed or refractory multiple myeloma (MM) - in combination with dexamethasone for adults who have received at least two prior treatment regimens, including both lenalidomide and a proteasome inhibitor

Information

Ygalo
New molecular entity
Oncopeptides
Oncopeptides

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Prodrug of melphalan and an alkylating peptide that stimulates caspase-3 and inhibits DNA synthesis
The incidence in Europe is 4.5-6.0 per 100,000/year with a mortality rate of 4.1 per 100,000/year [1].
Relapsed or refractory multiple myeloma (MM) - in combination with dexamethasone for adults who have received at least two prior treatment regimens, including both lenalidomide and a proteasome inhibitor
Intravenous infusion